At the news
? NEUTRALIMPACT 5/10 8-K filed Apr 30, 2026 at 16:40 ET
Summit Therapeutics reported Q1 2026 financial results and operational progress. The company posted a GAAP net loss of $189.4M ($0.24/share), wider than the $62.9M loss in Q1 2025, driven by increased R&D and stock-based compensation. Key catalysts include the upcoming ASCO 2026 presentation of HARMONi-6 overall survival data as a late-breaking abstract and the HARMONi-3 squamous cohort final PFS data expected in H2 2026, with the PDUFA date for ivonescimab BLA set for November 14, 2026.
- GAAP net loss of $189.4M ($0.24/share) in Q1 2026 vs $62.9M ($0.09/share) in Q1 2025
- Cash and short-term investments at $598.7M as of March 31, 2026, down from $713.4M at year-end 2025
- HARMONi-6 overall survival data selected as late-breaking abstract for ASCO 2026 Plenary Session on May 31, 2026
- HARMONi-3 squamous cohort interim PFS analysis completed; iDMC recommended study continue; final PFS data expected H2 2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access